Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma

2016-11-30 15:45:26 | BioPortfolio


BMS will conduct a regulatory postmarketing surveillance (PMS) to evaluate the safety of elotuzumab in clinical practice in Japan.

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Multiple Myeloma


No Intervention


Not yet recruiting


Bristol-Myers Squibb

Results (where available)

View Results


Published on BioPortfolio: 2016-11-30T15:45:26-0500

Clinical Trials [1252 Associated Clinical Trials listed on BioPortfolio]

Nivolumab + Lenalidomide + Dexamethasone In SMM

This research study is evaluating a new drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myelo...

Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma

This study involves receiving blinatumomab after high-dose melphalan and ASCT for multiple myeloma. The main purpose of this study is to: - To determine whether blinatumomab is safe and fe...

Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma

The primary goal of the study is to determine the best dose of an investigational drug to give to patients with multiple myeloma and to evaluate the investigational drug's effectiveness as...

Psychoeducational and Behavioral Strategies in Reducing Distress and Anxiety in Patients With Multiple Myeloma and Their Family Caregivers

This pilot clinical trial studies how well psychoeducational and behavioral strategies work in reducing distress and anxiety in patients with multiple myeloma and their family caregivers. ...

An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients

The purpose of this study is to describe contemporary, real-world disease and participant presentation, therapies, and clinical outcomes in both participants with newly diagnosed and not y...

PubMed Articles [11487 Associated PubMed Articles listed on BioPortfolio]

Polycythaemia: an unusual presentation of multiple myeloma.

In contrast to anaemia, polycythaemia is a distinctly uncommon finding in patients with multiple myeloma. We describe the presence of otherwise unexplained polycythaemia in a 57-year-old Caucasian man...

Glomerulonephritis as a Type of Kidney Injury in Multiple Myeloma: a Report of 2 Cases.

Renal involvement in multiple myeloma has multiple etiologies. Glomerulonephritis rarely occurs in multiple myeloma and numerous case reports in the literature explain their correlation. We report 2 c...

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal dam...

Engineered Nanoplatelets for Enhanced Treatment of Multiple Myeloma and Thrombus.

A platelet membrane-coated biomimetic nanocarrier, which can sequentially target bone microenvironment and myeloma cells to enhance the drug availability at the myeloma site and decrease the off-targe...

Correlation of Th17 Cells and IL-17 Level in Multiple Myeloma Patients with Pathogenesis of Multiple Myeloma.

To explore the correlation of Th17 cell rate and IL-17 level with pathogenetis of multiple myeloma(MM).

Medical and Biotech [MESH] Definitions

A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. It can be a primary manifestation of multiple myeloma or develop as a terminal complication during the disease.

Abnormal immunoglobulins characteristic of MULTIPLE MYELOMA.

A study that uses observations at multiple time points before and after an intervention (the "interruption"), in an attempt to detect whether the intervention has had an effect significantly greater than any underlying trend over time.

An abnormal protein with unusual thermosolubility characteristics that is found in the urine of patients with MULTIPLE MYELOMA.

A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA.

More From BioPortfolio on "Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma"

Quick Search

Searches Linking to this Trial